About this trial
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.
Eligibility criteria
Qualifiers
Person who has given written consent
Person with systemic scleroderma
Person who has given written consent
Person undergoing plastic, cosmetic and reconstructive surgery
Disqualifiers
Person not affiliated to or not benefiting from a social security scheme
Person subject to a legal protection measure (curatorship, guardianship)
Person subject to a legal protection measure
An adult who is incapable or unable to give consent
Trial design
Treatments tested in this trial
- Skin samples
- Analysis of fibroblasts